XUND is a technology company.
XUND has raised $8.0M across 2 funding rounds.
XUND has raised $8.0M in total across 2 funding rounds.
XUND is a Vienna-based health tech company founded in 2018 that builds an API-first Patient Interaction Suite, a certified class IIa medical device under EU MDR regulations. It provides AI-driven tools like Symptom Checkers, Illness Checkers, Health Checks, and Patient Monitoring to digitize patient journeys, offering health risk assessments, symptom analysis, diagnostic guidance, and navigation to appropriate care.[1][2][3][4][6] Serving digital health firms, payers, providers, pharma, and pharmacies, XUND solves key healthcare challenges such as accessibility, inefficient patient triage, and unstructured data by translating symptoms into actionable insights with 93% medical accuracy benchmarked against doctors, enabling scalable, compliant integrations for better decision-making.[1][3][4][5][6]
The company has gained traction with leading insurers, hospitals, and pharma partners across Europe, partnering on tools like the "Health Check" with Handelskrankenkasse (HKK), and holds certifications including ISO 13485, ISO 27001, and MDR 2017/745 for safety and compliance.[2][3][6][7]
XUND was founded in 2018 in Vienna, Austria, by a team blending technology, medicine, and human-centered design, driven by the mission to address healthcare accessibility—one of the biggest problems of the era—through evidence-based digital solutions.[1][3][4][7] The idea emerged from recognizing gaps in patient access and decision-making, leading to years of R&D using natural language processing (NLP) on millions of medical publications, verified by in-house physicians against reference literature and real-world data.[4][6]
Early pivotal moments included stress-testing the product for accuracy, achieving medical device certification, and securing partnerships with insurers and providers. This built a foundation for expansion, with recent funding enabling growth across Europe, the UK, and ambitions for the US, supported by a team of over 50 members across offices in Vienna, Budapest, London, and Berlin.[2][4][7]
XUND rides the AI-driven digital health wave, capitalizing on post-pandemic demand for remote triage, preventive care, and data-driven personalization amid staffing shortages and rising costs.[1][2][4] Timing aligns with EU MDR enforcement and global AI health adoption, where tools like conversational AI reduce routine burdens on providers—similar to competitors like Infermedica or Diagnostic Robotics but differentiated by full-journey MDR-certified APIs.[1][5]
Market forces favoring XUND include exploding telehealth (serving virtual-first providers), payer pressures for efficiency, and pharma's need for patient insights; it influences the ecosystem by enabling "digital front doors" that improve data flow, patient navigation, and outcomes across fragmented healthcare systems.[2][3][6]
XUND is poised for accelerated growth through European/UK scaling and US entry, expanding from triage to full preventive monitoring and treatment support via algorithm enhancements.[4] Trends like AI regulatory harmonization, multimodal data integration, and value-based care will amplify its role, potentially evolving it into a core infrastructure layer for health apps—much like how it started as a symptom checker to transform accessibility.[3][4][6] This positions XUND to deepen ecosystem impact, delivering clarity to healthcare's toughest decisions.
XUND has raised $8.0M in total across 2 funding rounds.
XUND's investors include Eurazeo, MassMutual Ventures, Pieter Kemps, Alberto Gutiérrez, Alexandros Bottenbruch, Andreas Mihalovits.
XUND has raised $8.0M across 2 funding rounds. Most recently, it raised $6.0M Seed in March 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2025 | $6.0M Seed | Eurazeo, MassMutual Ventures, Pieter Kemps, Alberto Gutiérrez, Alexandros Bottenbruch, Andreas Mihalovits | |
| Apr 1, 2024 | $2.0M Seed | Eurazeo, MassMutual Ventures, Pieter Kemps, Alberto Gutiérrez, Alexandros Bottenbruch, Andreas Mihalovits |